Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis

American Journal of Ophthalmology

Volumn 127, Issue 5, 1999, Pages 537-544

  Cohen, C R ^a   Davis, J ^a   DeBarge, R ^a   Foley, J ^a   Foster, C S ^a   Fox, K ^a   Friedlaender, M ^a   John, G ^a   Kaufman, A ^a   Nozik, R ^a   Olander, K ^a   Ostrov, C ^a   Raizman, M ^a   Rosenbaum, J ^a   Sall, K ^a   Sheppard, J ^a   Stewart, D ^a   Tauber, J ^a   Trocme, S ^a   Zimmerman, P ^a  

^a PHARMALOGIC DEVELOPMENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOTEPREDNOL ETABONATE; PREDNISOLONE ACETATE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PREDNISOLONE; PROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME; UVEITIS, ANTERIOR;

EID: 0032914924     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)00034-3     Document Type: Article

References (17)

1. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 4:1965;198-205.
2. Armaly M.F. Statistical attributes of the steroid hypertensive response in the clinically normal eye: I. The demonstration of three levels of response. Invest Ophthalmol. 4:1965;187-197.
3. Bodor N. Novel approaches to the design of safer drugs soft drugs and site-specific chemical delivery systems . Adv Drug Res. 13:1984;255-331.
4. Bodor N. Soft drugs principles and methods for the design of safe drugs . Med Res Rev. 4:1984;449-469.
5. Druzgala P., Wu W.M., Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 10:1991;933-937.
6. Manabe S., Bucala R., Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest. 74:1984;1803-1810.
7. Bucala R., Gallati M., Manabe S., Cotlier E., Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 40:1985;853-863.
8. Bartlett J.D., Horwitz B., Laibovitz R., Howes J.F. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 9:1993;157-165.
9. Howes J., Novack G.D. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite PJ-91 following chronic ocular administration. J Ocul Pharmacol Ther. 14:1998;153-158.
10. Asbell P.A., Howes J. A double-masked placebo-controlled, evaluation of the efficacy and safety of loteprednol etabonate in the treatment of contact-lens associated giant papillary conjunctivitis. CLAO J. 23:1997;31-36.
11. Friedlaender M.H., Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol. 123:1997;455-464.
12. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. Ophthalmology. 105:1998;1780-1786.
13. Stewart R.H., Horwitz B., Howes J., Novack G.D., Hart K. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. J Cataract Refract Surg. 24:1998;1480-1489.
14. Dell S.J., Shulman D.G., Lowry G.M. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of seasonal allergic conjunctivitis. Am J Ophthalmol. 123:1997;791-797.
15. Dell S.J., Lowry G.M., Northcutt J.A., Novack G.D., Hart K. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 102:1998;251-255.
16. Shulman D.G., Lothringer L.L., Rubin J.M., Briggs R.B., Howes J., Novack G.D. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 106:1999;362-369.
17. Stewart R.H., Smith J.P., Rosenthal A.L. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res. 3:1984;835-839.